xx
x5JUMF"4JOHMF4FRVFODF
0QFO-BCFM
1FSJPE
$SPTTPWFS4UVEZ UP&WBMVBUFUIF&GGFDUPGUIF
1SPUPO1VNQ*OIJCJUPS&TPNFQSB[PMFPOUIF4JOHMF%PTF1IBSNBDPL JOFUJDTPG0SBM5",JO
)FBMUIZ"EVMU4VCKFDUT
/$5/VNCFS/$5
1SPUPDPM"QQSPWF%BUF'FC
&HUWDLQLQIRUPDWLRQZLWKLQWKLVSURWRFROKDVEHHQUHGDFWHGLH VSHFLILFFRQWHQWLVPDVNHGLUUHYHUVLEO\IURP
YLHZZLWKDEODFNEOXH EDUWRSURWHFWHLWKHUSHUVRQDOO\LGHQWLILDEOHLQIRUPDWLRQ33' RUFRPSDQ\
FRQILGHQWLDOLQIRUPDWLRQ&&,
7KLVPD\LQFOXGHEXWLVQRWOLPLWHGWRUHGDFWLRQRIWKHIROOR ZLQJ
1DPHGSHUVRQVRURUJDQL]DWLRQVDVVRFLDWHGZLWKWKHVWXG\
3URSULHWDU\LQIRUPDWLRQVXFKDVVFDOHVRUFRGLQJV\VWHPVZKLF KDUHFRQVLGHUHGFRQILGHQWLDO
LQIRUPDWLRQXQGHUSULRUDJUHHPHQWVZLWKOLFHQVHKROGHU
2WKHULQIRUPDWLRQDVQHHGHGWRSURWHFWFRQILGHQWLDOLW\RI7DNHG DRUSDUWQHUVSHUVRQDOLQIRUPDWLRQRU
WRRWKHUZLVHSURWHFWWKHLQWHJULW\RIWKHFOLQLFDOVWXG\
TAKEDA PHARMACEUTICALS
PROTOCOL
A Single- Sequence, Open -Label, 2- Period, Crossover Study to Evaluate the Effect of the 
Proton Pump Inhibitor Esomeprazole on the Single -Dose Pharmacokinetics of Oral 
TAK -906 in Healthy Adult Subjects
Study Identifier: TAK-906-1006
Compound: TAK-906
Date: 04 Feb 2019
Version/Amendment 
Number:Final Protocol 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 2of 68
Protocol Final 04 Feb 2019
TABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 6
2.0 STUDY SCHEMATIC .................................................................................................. 10
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 12
4.0 INTRODUCTION ......................................................................................................... 14
4.1 Background for TAK -906 ........................................................................................ 14
4.2 Background for Esomeprazo le................................................................................. 14
4.3 Rationale for the Proposed Study ............................................................................. 15
4.4 Benefit/Risk Profile .................................................................................................[ADDRESS_915442] ives: Timing of Procedures ............... 20
6.4 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 20
6.5 Study  Beginning and End/Co mpletion..................................................................... 21
6.5.1 Definit ion of Beginning o f the Study .................................................................. 21
6.5.2 Definit ion of End of the Study ........................................................................... 21
6.5.3 Definit ion of Study  Com pletion......................................................................... 21
6.5.4 Definit ion of Study  Discont inuat ion................................................................... 21
6.5.5 Criteria for Premature Terminat ion or Suspension of the Study .......................... 21
6.5.6 Criteria for Premature Terminat ion or Suspension of a Site ................................ 21
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 3of 68
Protocol Final 04 Feb 2019
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. [ADDRESS_915443] Replacement ................................................................................................ 24
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 25
8.1 Clinical Study  Drug .................................................................................................25
8.1.1 TAK -906 Capsule .............................................................................................. 25
8.1.2 Esom eprazo le Capsule ....................................................................................... 25
8.1.3 Clinical Study  Drug Labeling ............................................................................. 25
8.1.4 Clinical Study  Drug Inventory  and Storage ........................................................ 25
8.1.5 Clinical Study  Drug Blinding ............................................................................. 25
8.1.6 Randomization Code Creation and Storage ........................................................ 26
8.1.7 Clinical Trial Blind Maintenance/Unblinding Procedure .................................... 26
8.1.8 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................... 26
9.0 STUDY PROCEDURES ............................................................................................... 27
9.1 Administrative Procedures ....................................................................................... 27
9.1.1 Inform ed Consent Procedure .............................................................................. 27
9.1.2 Inclusio n and Exclusio n..................................................................................... 27
9.1.3 Medical History /Dem ography ............................................................................ 29
9.1.4 Concomitant Medications ................................................................................... 29
9.2 Clinical Procedures and Assessments ....................................................................... 29
9.2.1 Full Physical Exam ............................................................................................ 29
9.2.2 Height and Wei ght............................................................................................. 30
9.2.3BMI ................................................................................................................... 30
9.2.4 Vital Signs ......................................................................................................... 30
9.2.5 12-Lead ECG ..................................................................................................... 30
9.2.6 Study  Drug Administration ................................................................................ 30
9.2.7 AE Monitoring ................................................................................................... 31
9.2.8 Laboratory  Proce dures and Assessments ............................................................ 31
9.2.9 Clinical Laboratory  Tests ................................................................................... 31
9.3 PK Sam ples............................................................................................................. 32
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-[ADDRESS_915444] AEs...........................................................................................38
10.2 AE Proce dures .........................................................................................................38
10.2.1 Assi gning Severity/Intensity of AEs ...................................................................38
10.2.2 Assi gning Causality of AEs ................................................................................39
10.2.3 Start D ate...........................................................................................................39
10.2.4 End Date ............................................................................................................40
10.2.5 Pattern of A dverse Event (Frequency) ................................................................[ADDRESS_915445] ical and Analytical Plans ................................................................................44
11.1.1 Analysis S ets......................................................................................................44
11.1.2 Analysis of Demography and Ot her Baseline Cha racteristi cs .............................44
11.1.3 PK Analysi s .......................................................................................................44
11.1.4 PD Analysi s .......................................................................................................45
11.1.5 Safety Analy sis ..................................................................................................45
11.2 Interim Analysis and Criteria for Early Termination ................................................45
11.3 Determination of Sample Size ..................................................................................45
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ...............................................47
12.1 Study-Site Monit oring Visits ...................................................................................47
12.2 Protocol Dev iations..................................................................................................47
12.3 Qu ality Ass urance Audits and Regulatory Agency Inspections ................................47
13.0 ETHICAL ASPECTS OF THE STUDY........................................................................48
13.1 IRB and/or IEC Approval ........................................................................................[ADDRESS_915446] Confidentiality ............................................................................................50Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use344
........[ADDRESS_915447] of Abbreviat ions......................................................................................... 55
15.0 DAT A HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] ............................................................ 57
15.1 CRFs (El ectronic and/or Paper) ................................................................................ [ADDRESS_915448] igator Consent to the Use of Personal Information .................................... 66
Appendix D Pregnancy and Contraception ............................................................................. 67
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_915449]
Camb ridge, [LOCATION_005] [LOCATION_003] 02139Compound:
TAK -906
Study Identifier: TAK -906-1006 (CA27239) Phase: 1
Protocol Titl e: A Single -Sequence, Open -Label, [ADDRESS_915450] of the Proton Pump 
Inhibitor Esomeprazole on the Single -Dose Pharmacokinetics of Oral TAK -906 in Healthy Adult Subjects
Study Design:
This is a single -sequence, open -label, [ADDRESS_915451] of a proton pump inhibitor (PPI) esomeprazole on the PK of TAK -906.
The study will include a Screening Visit, Study Period 1 (Days 1 to 3), followed by [CONTACT_2669] a 4 -day washout (from the 
time of TAK -906 dose on Day 1), Study Period 2 (Da ys 1 to 6), and finally a Follow -up Visit. 
In Study Period 1, subjects will be confined from the day prior to dosing (Day -1), at the time indicated by [CONTACT_117599] (CRU) , until after the 48 -hour blood draw (Day 3). In Study Period 2, subjec ts will come to the CRU on 
the mornings of Day 1 and Day 2, at the time indicated by [CONTACT_47365], for dosing and/or study procedures as appropriate. 
Subjects will be confined from morning of Day 3, at the time indicated by [CONTACT_47365], until after the [ADDRESS_915452] may be required to remain at the CRU for longer at the discretion of the Investigator.
On Day  1 of Study  Period 1, subjects will receive a single oral dose of TAK -906. On Days 1 through 5 of Study 
Period 2, subjects will receive esomeprazole dose once daily (QD). On Day 4 of Study Period 2, a single oral dose of 
TAK -906 will be administered 1 hour following the esomeprazole dose. Serial blood samples will be collected 
predose and for 48 hours after each TAK -906 dose t o determine the pharmacokinetics (PK) of TAK -906. 
There will be a washout of at least [ADDRESS_915453] one dose of study drug (including subjects who terminate the study early) will return 
to the Clinical Research U nit (CRU) approximately 10-[ADDRESS_915454] dose of TAK -906 for follow -up 
procedures, and to determine if any adverse event (AE) has occurred since the last study visit. 
ï‚·Study Primary Objective :
ï‚·To evaluate the effect of the PPI [INVESTIGATOR_676787] -dose PK of orally (PO) administered TAK -906.
ï‚·Secondary Objectives:
ï‚·To evaluate the safety and tolerability of a single PO dose of TAK -[ADDRESS_915455] Population: Males and females (with no childbearing potential) aged 18 to 55 years, inclusive, at the 
Screening Visit. Body ma ss index (BMI) â‰¥18.0 and â‰¤30.0 kg/m2at screening.
Planned Number of Subjects:
12Planned Number of Sites:
1
Dose Levels:
Study Period 1 (Treatment A): 
25 mg TAK -906 (1 x 25 mg TAK -906 capsule) 
Study Period 2 (Treatment B):
40 mg esomeprazole (1 x 40 mg NEXIUMÂ®capsule, or 
generic equivalent) 
25 mg TAK -906 (1 x 25 mg TAK -906 capsule)Route of Administration:
Oral
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 7of 68
Protocol Final 04 Feb 2019
Duration of Treatment:
On Day  1 of Study  Period 1, subjects will receive a 
single oral dose of TAK -906.
On Day s 1 through 5 of Study Period 2, subjects will 
receive QD doses of esomeprazole. On Day 4 of Study 
Period 2, subjects will receive a single oral d ose of 
TAK -906 1 hour following esomeprazole dose. Planned Study Duration :
Approximately 50 days including Screening Period
Main Criteria for Inclusion:
Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study : 
1.Healthy , adult, male or female, [ADDRESS_915456].
3.Body mass index (BMI) â‰¥18.0 and Ë‚30.0 kg/m2at screening. 
4.Medically healthy with no clinically significant medical histor y, physical examination, laboratory profiles, vital 
signs or electrocardiographs (ECGs), as deemed by [CONTACT_337435].
5.For a male or female of non -childbearing potential, use acceptable birth control methods as indicated in Appendix 
D.
6.A male subject who is nonsterilized and sexually active with a female partner of childbearing potential must agree 
to use a barrier method of contraception from the signing of informed consent form (ICF) throughout the duration of the study and through to the follow up (ie, [ADDRESS_915457] dose of TAK -906) (refer to Appendix D).
7.If male, must agree not to donate sperm from the first dosing until follow -up visit (ie, [ADDRESS_915458] dose 
of TAK -906) (refer to Appendix D).
8.Understands the study procedures in the informed consent f orm (ICF), and be willing and able to comply with the 
protocol.
Main Criteria for Exclusion:
The subject must be excluded from participating in the study if the subject: 
1.Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or 
expected during the conduct of the study.
2.Histor y or presence of clinically significant endocrine, gastrointestinal (including motility disorder and intestinal 
obstruction), cardiovascular, hematological, hepatic, immunol ogical, renal, respi[INVESTIGATOR_1516], genitourinary, or major 
neurological (including stroke and chronic seizures) or any other clinically significant abnormalities or disease in the opi[INVESTIGATOR_25279].
3.Histor y of any illness that, in the opi[INVESTIGATOR_25279], might confound the results of the study or 
poses an additional risk to the subject by [CONTACT_47361].
4.Histor y of cancer (malignancy).
5.Histor y or presence of alcoholism or drug abuse within th e past [ADDRESS_915459] dosing. 
6.Histor y or presence of hypersensitivity or idiosyncratic reaction to TAK -906 or related compounds, or to 
esomeprazole or PPIs (see NEXIUM
Â®US product insert [USPI]).
7.Female subjects of childbearing potential.
8.Female subjects with a positive pregnancy test or who is lactating.
9.Positive urine drug or alcohol results at screening or first check -in. 
10.Positive urine cotinine at screening. 
11.Positive results at screening for human immunodefici ency virus (HIV), hepatitis B surface antigen (HBsAg), or 
hepatitis C virus (HCV).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-906
Study ID TAK-906-1006 Page 8 of 68Protocol Final 04 Feb 2019
12. QTcF interval is >450 msec or ECG findings are deemed abnormal with clinical significance by [CONTACT_337420].
13. Estimated creatinine clearance <90 mL/min at screening. 
14. Unable to refrain from or anticipates the use of:
!Any drug, including prescription and non-prescription medications (including PPIs, antacids, and 
H2-antagonist), herbal remedies, or vitamin supplements within [ADDRESS_915460] dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the Investigator or designee.
!Any drugs known to significantly affect the absorption, distribution, metabolism, or elimination of study 
drugs (TAK-906 or esomeprazole) within [ADDRESS_915461] dosing and throughout the study. 
Appropriate sources (eg, Flockhart Table
TM) will be consulted to confirm lack of PK/pharmacodynamic 
interaction with study drug.
15. Has been on a diet incompatible with the on-study diet, in the opi[INVESTIGATOR_25279], within the 
[ADDRESS_915462] dosing and throughout the study.
16. Donation of blood or significant blood loss (eg, approximately 500 mL) within [ADDRESS_915463] blood collection or dosing, whichever is later, in the previous 
study to Day 1 of Study Period 1 of the current study.
Main Criteria for Evaluation and Analyses:
The primary endpoint of the study is:
The following plasma PK parameters for TAK-906 on Day 1 in Study Period 1 and on Day 4 in Study Period 2:
!Cmax: Maximum observed concentration.
!AUC last: Area under the concentration-time curve from time [ADDRESS_915464] quantifiable concentration.
!AUC inf: Area under the concentration-time curve from time 0 to infinity.
The secondary endpoints include the following:
!Treatment emergent adverse event (TEAE) assessments.
!Vital signs.
!12-lead ECG.
!Clinical laboratory testing (hematology, serum chemistry and urine analysis).
CCI
Property ofyoFor non-commercial use only [ADDRESS_915465] After firs
estigatorstigato
r eliminatelimina
hroughout oughout
k of PK/phof PK/
e InvInvestigaesti
mL) withinL) with
ives priores prio
ollection llectionmrm
dverse eveerse e
boratory teboratorly
yoof [COMPANY_005]: Fo
TAK -906
Study ID TAK -906-1006 Page 9of 68
Protocol Final 04 Feb 2019
Statistical Considerations:
For evaluation of potential effect of esomeprazole on TAK -[ADDRESS_915466] -squares means (LSM) as well as the difference between  
treatment LSM. The geometric mean of the relative bioavailability of the TAK -906 w ith esomeprazole regimen 
relative to the TAK -906 regimen alone and the associated 90% CIs will be determined by [CONTACT_676795] -transformed parameters.
Sample Size Justification:
A total of twelve (12) subjects will be enrolled in this study. This sample size will provide at least 80% power to 
conclude the C maxof TAK -906 will not decrease more than 50% in the presence of esomeprazole , assuming that the 
intra-subject %CV for C maxof TAK -906 will not exceed 45% and a true ratio of 0.8. Lower intra -subject variability 
was observed for AUC in previous studies; therefore, the power is expected to be greater for AUC .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 10of 68
Protocol Final 04 Feb 2019
2.0 STUDY SCHEMATIC
Figure 2.a Schematic of Study Design
Screening Study Period 1 a
Within Day -28 to -2 
for screening; first 
dosing in Study 
Period [ADDRESS_915467] 48 hours 
postdose
< ------------  Confinement b, c------------>
a There will be a washout of at least [ADDRESS_915468] may be required to remain at the CRU for longer at the discretion of the Investigator or designee.
cSubjects will start the confinement on Day -1 of Study Period 1 and be released from CRU after Day 3 study 
assessments are complete. In Study Pe riod 2, subjects will return to the CRU on the morning of Days 1 and 2 for 
dosing and/or study procedures as appropriate. Subjects will be confined from morning of Day [ADDRESS_915469] 48 hours postdose
Outpatient visit < ------------Confinement c, d------------>
a There will be a washout of at least [ADDRESS_915470] one dose of study drug (including subjects who terminate the study early) will 
return to the CRU approximately [ADDRESS_915471] may be required to remain at the CRU for longer at the discretion of the Investigator or designee.
dIn Study Period 2, subjects will return to the CRU on t he morning of Days 1 and 2 for dosing and/o r study procedures 
as appropriate. Subjects will be confined from morning of Day 3 of Study Period 2, at the time indicated by [CONTACT_47365], until after 48 -hour blood draw on Day 6. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 11of 68
Protocol Final 04 Feb 2019
Figure 2.b Schematics of Single -Sequence Design
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 12of 68
Protocol Final 04 Feb 2019
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES 
Screening Study Period 1 (a)Study Period 2 Follow -up
Procedures/AssessmentsDay -28to-[ADDRESS_915472] dose of 
TAK -906
-1Predose
(Day 1) 1 2 3 1 2 3 4 5 6
Adm inistrative Procedures
Informed consent X
Inclusion/exclusion criteria X X
Medical history/demographics X
Prior and concomitant medication 
review------------------------------------ Continuous Monitoring ------------------------------------
Clinical Procedures/Assessments
Full physical examination X X (b)X
Height X
Weight X
BMI X
12-Lead Safety ECG X X (c), (b)X (c)X X (c)X (h)X
Supi[INVESTIGATOR_32832] (heart rate, systolic blood pressure and diastolic blood pressure)X X 
(c),(b)X (c)X X (c)X (h)X
Vital signs (respi[INVESTIGATOR_697], oral [at the floor of the mouth]/tympanic temperature)X X
TAK -906 administration(d)X X
Esomeprazole administration (e)X X X X X
AE monitoring ------------------------------------ Continuous Monitoring ------------------------------------
Laboratory Procedures/Assessments
Hematology X X X (b)X (h)X
Urinalysis X X X (b)X (h)X
Chemistry X X X (b)X (h)X
Serum Pregnancy Test ( â™€only) X X
Serum FSH (PMP â™€only) X
Urine drug screen X X X
Urine alcohol test (f)X X X
Urine cotinine test X
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-906
Study ID TAK-906-1006 Page 13 of 68
Protocol Final 04 Feb 2019
CONFIDENTIALScreening Study Period 1 (a)Study Period 2 Follow-up
Procedures/AssessmentsDay -[ADDRESS_915473] dose of 
TAK-906
-1Predose
(Day 1) 1 2 3 1 2 3 4 5 6
Hepatitis screen X
Human immunodeficiency virus (HIV) X
Pharmacokinetics Evaluations
Blood for plasma TAK-906 (g)X--------------------------X X---------X
Other
Confinement X--------------X X--------------X
Returns (i)XX
Meals fasting X X X X X X X
(a) There will be a minimum 4-day washout between Study Periods [ADDRESS_915474] udy Period 1.
(b) Day 1 predose assessment may be done within approximately 24 hours prior to study drug administration.(c) Measured predose and at 1, 2, 4, 8, and 48 hours postdose (times relative to TAK-906 dose). Subjects should have rested in a  supi[INVESTIGATOR_21683] 5 minutes before the 
measurements. 
(d) Both doses of TA K-906 (Day 1 of Study Period 1 and Day 4 of Study Period 2) will be administered after an overnight fast of  at least [ADDRESS_915475] 4 hours postdose. For Study Period 2, TAK-906 will be administered 1 h after esomeprazole dose on Day 4. 
(e) Esomeprazole will be administered once daily at the same time each day and [ADDRESS_915476] 2 hours postdose.
(f) An alcohol breath test may be performed at the discretion of the Investigator.(g) Blood samples for TAK-906 assay will be collected on Day 1 of Study Period 1 and Day 4 of Study Period 2 predose and at 0.5 , 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours 
postdose (times relative to TAK-906 dose). The 16-hour postdose on Day 1 of Study Period 1 and Day 4 of Study Period 2 will be e ither on Day 1 or Day 2 of Period 1 and Day 4 or 
Day 5 of Study Period 2, depending on the time of dosing on Day 1 of Study Period 1 and Day 4 of Study Period 2, respectively.
(h) To be performed on Day 6 of Study Period 2 or prior to early termination from the study. 
(i) Subjects will return to the CRU every morning on Days 1 and 2 of Study Period 2 to receive the esomeprazole dosing (Â± 1 hou r of Day 1 dosing). 
Abbreviations: â™€= Female, AE = Adverse events, BMI = Body mass index, CRU = Clinical research unit, DNA = Deoxyribose nucleic acid, ECG = Electrocardi ogram, 
HIV = Human immunodeficiency virus, PMP = Postmenopausal, PK = Pharmacokinetics.CCI
CCI
Property of [COMPANY_005]: For non-commercial use only and subds uub
dddsdnddddanyyyyyyy m administadmin
udy y drug addrug
K-906 dos906 d
od 2) will bod 2) wil
steeredred11h
day and 1ay and
t least [ADDRESS_915477] 2
he InvestigInvesti
y 1 of Stud1 of Stu
stdose on Dose on
g on Day 1on Day
ior to earlyr to ea
on Days 1 Days
ts, BMI, BMI =
=PostmePostmbject to the applicable Terms of Usebleabablic
4apppppppp
hep
hehehehehehehethhh
ttttttttotttottctttet
bjeceeecbjejejejubj
TAK-906
Study ID TAK-906-1006 Page 14 of 68Protocol Final 04 Feb 2019
4.0 INTRODUCTION
4.1 Background for TAK-906
The intended indication for TAK- 906 is to treat patients with gastroparesis, a disorder of the 
stomach characterized by [CONTACT_676796]. 
Symptoms are chronic with epi[INVESTIGATOR_145356] [1]. These symptoms may commonly 
include nausea, vomiting, early satiety, abdominal  pain, and postprandial fullness. The prevalence 
of gastroparesis in the [LOCATION_002] (US) is estimated to be approximately 24.2 per 100,000 [2]. In 
cases of chronic gastroparesis, diabetic (29%), postsurgical (13%), and idiopathic (36%) etiologies 
comprise the majority of cases in the tertiary referral setting [3].
TAK-906 is a peripherally selective (ie, very limited penetration of the blood brain barrier [BBB]) 
dopamine D2/D3 receptor antagonist. It demonstrated suitable PK and PD activity in a phase [ADDRESS_915478] the use.  Because of its low BBB penetration and a weak 
human ether-a-go-go-related gene (hERG) channel affinity indicative of a low potential cardiac 
risk, TAK-[ADDRESS_915479] an improved safety profile, compared to other D2/D3 
antagonist (eg, metoclopramide and domperidone). 
The solubility of TAK-906 is pH dependent (decreases with the increase of pH), and it is classified 
as a Biopharmaceutical Classification System class IV drug. Studies of in vitro metabolism 
suggest that TAK-906 is mainly metabolized by [CONTACT_097]2C8 and CYP3A4/5,
 
 The relative contribution ratio of CYP and non-CYP toward in vitro
metabolism of TAK-906 using human hepatic S9 cell line was 43.3% and 56.7%, respectively. 
TAK-906 is also a substrate of P-glycoprotein (P- gp), organic anion-transporting polypeptide 
(OATP)1B1 and OATP1B3. 
TAK-906 shows rapid absorption and rapid elimination. Median T maxwas 1.1 hours postdose. The 
half-life (TÂ½) following a single PO dose averaged approximately [ADDRESS_915480] on reducing the exposure to TAK-906 in healthy subjects. 
Coadministration of itraconazole 200 mg for 5 da ys with TAK- 906 maleate incr eased TAK-906 
mean C maxby [CONTACT_3450] 2.0-fold and AUCinf by [CONTACT_3450] 1.3-fold. TAK-906 is not 
classified as a sensitive CYP3A4 substrate.
Refer to the Investigatorâ€™s Brochure (IB) for detailed background information on TAK-906 [4]. 
4.2 Background for Esomeprazole
Esomeprazole, the S-enantiomer of omeprazole, is a PPI [INVESTIGATOR_676788] H+ ion formation through inhibition of the H+/K+ ATPase enzyme system at the 
secretory surface of gastric parietal cells. Esomeprazole is indicated for the treatment of heartburn 
and other symptoms associated with gastroesophageal reflux disease and, in combination with CCI
Property of [COMPANY_005]: For non-commercial uative conive co
man hepaan hep
P-glycopglyco
bsorptionorptio
ng a singg a sin
llowing owin
re to TAe to TA
ignificanignific
stration oratio
maxmaxby [CONTACT_676797]. tion
y cocommomm
The prevThe pre
per 100,0r 100,
thic hic (36%([ADDRESS_915481] one hour before meals [5]. 
After oral  adm inistrati on of  esomeprazo le capsule formulat ion, C maxoccurs at approximately  
1.5hours (T max). At repeated QD dosing with 40 mg, the systemic bioavailabilit y is approximately 
90% compared to 64% after a single dose of 40 mg [ 5]. The administration of food with 
esomeprazo le reduces AUC and C maxby 43 to 53% and 33 to 53%, respectively; however this does 
not have a significant influence on the effect of esomeprazo le on intra -gastri c acidity [6]. 
Esom eprazo le is 97% bound to plasma proteins [ 5]. Esomeprazo le is acid -labile and rapi[INVESTIGATOR_676789], but i s very  stable in alkaline media. Esomeprazo le has been 
shown to be optically stable and the degree of inversion to be negligible [5]. 
Esom eprazo le is extens ively metabo lized in the liver (to a lesser extent than racemic omeprazo le), 
primarily by  [CONTACT_097]2C19 and CYP3A to form the hydroxy , desm ethyl, and sulfo ne metabolites. 
None of the ident ified metabolites exhibit any of the significant ant i-secretory  effects di splayed by 
[CONTACT_676798] [ 5]. 
Eliminat ion of the drug is rapid with a terminal eliminat ion half -life of about 1.3 hours. 
Approximately  80% of  anoral dose of eso meprazole is excreted as inactive metabo lites in the 
urine, and 20% in feces. Less than 1% of the parent drug is excreted unchanged in the urine [ 5]. 
The m ost comm on adverse react ions associated with esomeprazo le administration are: headache, 
abdo minal pain, const ipation, diarrhea, flatul ence, nausea, and dry  mouth [5]. 
4.3 Rationale for the Proposed Study
The so lubility of TAK -906 is pH dependent (decreases wit h the increase o f pH). PPIs are 
commo nly used by [CONTACT_676799]. This group of agents 
suppresses gastric acid secretion by [CONTACT_676800] H+/K+-ATPase pum p in gastri c 
parietal cells, thereby  [CONTACT_676801] a sustained t ime, and thus may alter the 
bioavailabilit y of drugs wi th pH-dependent solubilit y when used together.
Esom eprazo le is widely prescribed. It is known to have a strong anti -secretory  effect, suppressing 
the production of gastric acid from parietal cells, and increasing pH. Esomeprazole is expected to 
lack the potential to interact directly wit h TAK -906, for example through CYP3A4 metabo lic 
interact ion [7]. In addition, eso meprazo le has a good safety and tolerabilit y profile, and was found 
to be well tolerated in healt hy vo lunteers [8].
4.4 Benefit/Risk Profile
The dose of TAK -[ADDRESS_915482] -in-human phase 1 study , a single 
dose of 25 mg TAK -906 i s expected to be well tolerated. 
The dose of eso meprazo le administered in this study is not anticipated to induce any potential risk 
or benefit to subjects participat ing in this study , and i t is administered according to the dosing 
recommendat ions found in the full pr escribing info rmation for NEXIUMÂ®[5].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_915483] ices emplo yed by  [CONTACT_3181]  (ie, 12 -lead ECG, vital signs, clinical 
laborator y tests, AE questioning, and physical examinat ion) are adequate to protect the subjectsâ€™ 
safet y and shoul d detect all TEAEs.
There will be no direct healt h benefit for study participants from receipt of study drug. An indirect 
healt h benefit to the healt hysubjects enro lled in this study is the free medical tests received at 
screening and during the study .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-906
Study ID TAK-906-1006 Page 17 of 68Protocol Final 04 Feb 2019
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Hypothesis
NA
5.2 Study Objectives5.2.1 Study Primary Objective
!To evaluate the effect of the PPI, esomeprazole, on the single-dose PK of PO administrated
TAK-906.
5.2.2 Study Secondary Objective
!To evaluate the safety and tolerability of a single PO dose of TAK-906 in the presence and
absence of the PPI, esomeprazole.
5.3 Endpoints5.3.1 Primary Endpoint
The primary endpoint of the study is:
The following plasma PK parameters for TAK-906 on Day 1 in Study Period 1 and on Day 4 in 
Study Period 2
!C
max: Maximum observed concentration.
!AUC last: Area under the concentration-time curve from time [ADDRESS_915484] quantifiable
concentration.
!AUC inf: Area under the concentration-time curve from time 0 to infinity.
5.3.2 Secondary Endpoints 
Secondary endpoints include: 
!TEAE assessments.
!Vital signs.
!12-lead ECG.
!Clinical laboratory testing (hematology, se rum chemistry, and urine analysis).
5.3.3 Explor atory Endpoints
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Usef PO admPO adm
f TAKTAK -9
TAKAK--[ZIP_CODE]
entrationntratio
ncentraticentr
the conche co
y EndpoEndp
dpoints idpoints
assessmasses
italali sign sigll
12-12-leal
!!C
TAK-906
Study ID TAK-906-1006 Page 18 of 68Protocol Final 04 Feb 2019
CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Useable T
TAK -[ADDRESS_915485] of a PPI [INVESTIGATOR_676790] -906. 
The study  will include a Screening Visit, a Study  Period 1 (Day s 1 to 3), fo llowed by [CONTACT_2669] a 
4-day washout from  the time of TAK -906 dose, a Study  Period 2 (Day s 1 to 6), and a Follow -up 
Visit. 
Screening of subjects will occur within [ADDRESS_915486] dosing.
In Study  Period 1, subjects will be confined from the day  prior to dosing (Day  -1), at the time 
indicated by  [CONTACT_47365], until after the 48 -hour blood draw (Day 3). In Study Period 2, subjects will 
come to the CRU on the mornings of Day 1 to Day 2, at the time indicated by [CONTACT_47365], for dosing 
and/or study  procedures as appropriate. Subject s will be confined from morning of Day 3, at the 
time indicated by [CONTACT_47365], until after the 48-hour blood draw on Day 6. At any time, a subject ma y 
be required to remain at the CRU for longer at the discretion of the Investigator.On Day  [ADDRESS_915487] one dose of study drug (including subjects who terminate the 
study  early ) will  return to the CRU approximately [ADDRESS_915488] anned dose l evels o f TAK -906 and esomeprazole to be used are outlined in Table 6.a. 
Table 6.a Study Drugs Planned Dose Levels 
DoseRoute of 
Administration
Study Period 1 (Treatment A)
TAK -906 25 mg Oral capsule
Study Period 2 (Treatment B)
TAK -906 25 mg Oral capsule
Esomeprazole 40 mg Oral capsule
6.2 Dose Escalation
NA
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_915489] on acid secretion due to its irreversible binding to 
H+/K+ ATPase pump, a single -sequence design in which eso meprazo le is administered in Study  
Period2 was selected to ensure that there is no carryover pharmacodynamic effect on gastric acid 
secretion for the reference treatment (TAK -906 al one).
The washout period between TAK -906 doses in each period is considered sufficient to ensure 
minimal carry over effects of the TAK -906.
6.3.2 Rationale for Dose 
TAK -906: Based on the first -in-human phase [ADDRESS_915490] been well -tolerated in healthy men and wo men. 
Overall, the incidence of TEAEs was low in the study. There were no SAEs or severe AEs reported 
during the study , and no subjects di scont inued due to an AE. Based on the results of the clinical 
studi es, 25 mg dose of TAK -906 is expected to be the clinically efficacious dose that is well below 
the maximum tested dose of 300 mg.
Esomeprazole: A dose of 40 mg eso meprazole daily is wit hin the recommended dose as 
prescribed in the labe ling [ 5]. In addition, mult iple doses will ensure maximum inhibit ion of acid 
secretion by [CONTACT_676802] [6]. The m aximum  recommended dose of esomeprazole (40 mg per 
day) was selected to ensure that any  possible PK interactions are detected. 
6.3.[ADDRESS_915491] relevant PK parameters for the purpose 
of eval uating an interaction. 
6.3.4 Critical Procedures Based on Study Objectives: Timing of Pro cedures 
For thi s study , the bl ood collect ion for plasma concentrati ons for TAK -906 is the cri tical 
procedure and samples are required to be collected, as appropriate, as close to the scheduled times 
defined in this protocol as possible.
6.4 Study Design/Dosin g/Procedures Modifications Permitted Within Protocol 
Parameters
The dose and administration of the study drugs to any subject may not be modified. If necessary a 
subject must be discont inued for the reasons described in Sect ion 6.5.5 .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 21of 68
Protocol Final 04 Feb 2019
6.5 Study Beginning and End/Completion
6.5.1 Definition of Beginning of the Study
The beginning of the study  will be defined as the beginning of the screening (ie, signing of the
ICF) of the first subject.
6.5.[ADDRESS_915492] scheduled study  procedure as outlined in the 
Schedule of Study  Procedures (Section 3.0).
6.5.[ADDRESS_915493] anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
ï‚·New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participat ing in the study .
ï‚·Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study  objectives or compromises subject safet y.
6.5.6 Criteria for Premature Termination or Suspension of a Site
NA
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 22of 68
Protocol Final 04 Feb 2019
7.0 SELECTION AN D DISCONTINUATION/WI THDRAWAL OF SUBJECTS
7.[ADDRESS_915494] ion [IP_ADDRESS] . 
After the first dose, acetaminophen (up to 2 g per 24 hour period) may be administered at the 
discreti on of  the Investi gator or desi gnee. Thy roid horm one repl acement m edicat ion may be 
permit ted if the subject has been on the same stable dose for the immediate [ADDRESS_915495] may cont inue participat ion in the study .
All medications taken by [CONTACT_47378].
Use of excluded agents (prescript ion or non -prescript ion) or dietary  products i s outlined in 
Table 7.a.
Table 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and First Dosing 
(Days -28 to predose [Day 1])Post First Dosing (Day 1) to Follow -Up 
Alcohol Prohibited from [ADDRESS_915496] dosing in 
each period and throughout until end of PK collection in Treatment Period 2.
Xanthine and/or caffeine Prohibited from [ADDRESS_915497] dosing in 
each period until end of PK collection in Study 
Period 2
Medications See Sections 7.1and [IP_ADDRESS] See Sections 7.1and [IP_ADDRESS]
Food substance
Grapefruit/Seville orange Prohibited from [ADDRESS_915498] green 
family (eg, kale, broccoli, 
watercress, collard greens, kohlrabi, 
Brussels sprouts, mustard), and 
charbroiled meatsProhibited from [ADDRESS_915499] dosingProhibited until end of PK collection in Study Period 2.
asmall amounts of caffeine derived from normal foodstuffs eg, 250 mL/8 oz./1 cup decaffeinated coffee or o ther decaffeinated 
beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this 
restriction. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 23of 68
Protocol Final 04 Feb 2019
7.2 Diet, Fluid, Activity 
7.2.1 Diet and Fluid
Water (except water provided wit h each oral dosing) w ill be restri cted [ADDRESS_915500] from all food 
and drink except water between meals and snacks.
Each m eal and/or snacks served at the CRU will be standardized and will be similar in caloric 
content and composit ion and will be taken at approximately  the same time in each treatment 
period.
7.2.[ADDRESS_915501] igator or designee for the 
following reasons:
ï‚·AEs.
ï‚·Difficult ies in blood collect ion.
ï‚·Positive pregnancy  test.
ï‚·Positive drug and alcoho l test.
A subject may be wit hdrawn by [CONTACT_11856] (or designee) or the Sponsor if enrollment into the 
study  is inappropriate, the study plan is vio lated, or for administrative and/or other safet y reasons.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_915502]â€™s study participat ion at any t ime during the study when 
the subject meets t he study termination criteria described in Section 7.3. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subjectâ€™s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
[CONTACT_24342]. In additio n, efforts should be made to perform all procedures scheduled for the 
follow-up or early  terminat ion as described in Sectio n 3.0. 
7.[ADDRESS_915503] igator in consultat ion with the Sponsor. Subjects who discont inue for safet y reasons will not 
be replaced.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_915504]. 
8.1.2 Esomeprazole Capsule 
Once -daily (QD) 40 m g dose of esom eprazo le capsules ( NexiumÂ®capsule, or generic e quivalent ) 
will be administered on Days [ADDRESS_915505]. 
8.1.3 Clinical Study Drug Labeling
TAK -906 capsule containers will be affixed with a clinical label in accordance with local 
regul atory  requi rements.
Esom eprazo le capsule will be provided with the comm ercially  available package and labeling in 
accordance with local regulatory  requi rements.
8.1.4 Clinical Study Drug Inventory and Storage
The Sponsor will supply sufficient quant ities of TAK -906 products to allow co mpletion of this 
study . 
Celeri on will provi de sufficient quantit ies of eso meprazole capsules to allow co mpletion of the 
study . The same l ot number will be used throughout the study .
The l ot numbers and expi[INVESTIGATOR_39743] (where available) of the study  drugs supplied will be 
recorded in the final report.
Records will be made of the receipt, preparation, dispensing, and final disposit ion of the study  
drugs supplied. All study drugs will be prepared and labeled by [CONTACT_676803]. 
8.1.5 Clinical Study Drug Blinding
This is an open -label study .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 26of 68
Protocol Final 04 Feb 2019
8.1.6 Randomization Code Creation and Storage 
NA
8.1.7 Clinical Trial Blind Maintenance/Unblinding Procedure
NA8.1.[ADDRESS_915506] accountabilit y records.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 27of 68
Protocol Final 04 Feb 2019
9.0 STUDY PROCEDURE S
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
The purpose of the study , the procedures to be carried out and the potential hazards will be 
described to the subjects in non -technical terms. Subjects will be required to read, sign, and date an 
ICF s ummari zing the discussio n prior to screening, and will be assured that they  may withdraw 
from the study  at any  time wi thout jeopardi zing thei r medical  care.
Subjects will be given a copy  of their si gned ICF.
[IP_ADDRESS] Assignment of Screening and Randomization Number s 
Each subject will be assigned a unique ident ificat ion number upon screening. Subjects who 
complete the study  screening assessments and meet all the eligibilit y criteria will be assigned a 
unique identificat ion number at the time of the first dosing, dif ferent from the screening number.
If replacement subjects are used, the replacement subject number will be 100 more than the 
original  (eg, Subject No. [ADDRESS_915507] No. 1).
[IP_ADDRESS] Study Drug Assignment
This i s a fixed- sequence ([ADDRESS_915508] crossover) study . All subjects will receive the same treatments as 
detailed in Sect ion6.1.
9.1.2 Inclusion and Exclusion 
[IP_ADDRESS] Inclusion Criteria 
Subjects m ust fulfill all o f the following inclusio n criteria to be eligible for participat ion in the 
study : 
1.Healthy, adul t, male or female, [ADDRESS_915509].
3.Body  mass index (BMI) â‰¥18.0 and Ë‚30.0 kg/m2at screening. 
4.Medically  healthy wi th no clinically  significant m edical history , physical examinat ion, 
laboratory  profiles, vi tal signs or ECGs, as deemed by  [CONTACT_676804].
5.For a m ale or female o f non-childbearing potential, use acceptable birth control methods as 
indicated in Appendix D.
6.A male subject who is nonsterilized and sexually active wit h a female partner of childbearing 
potenti al must agree to use a barrier method of contraception from signing of the ICF 
throughout the duration of the study  and through to the follow up (ie, 10- [ADDRESS_915510] 
dose of TAK -906) (refer to Appendix D).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_915511] dosing unt il follow-up visit (10- [ADDRESS_915512] dosing).
8.Understands the study  procedures i n the ICF, and be willing and able to comply  with the 
protocol .
[IP_ADDRESS] Exclusion Criteria
The subject must be excluded fro m participat ing in the study if the subject: 
1.Is mentally  or legally incapacitated or has significant emotional problems at the time of the 
screening visit or expected during the conduct of the study .
2.History  or presence of clinically significant endocrine, gastrointestinal (includ ing motility 
disorder and intestinal obstruction), cardiovascular, hematological, hepatic, immunological, 
renal, respi[INVESTIGATOR_57774], genitourinary, or major neuro logical (including stroke and chronic seizures) 
any other clinically significant abnormalit ies or dis ease in the opi[INVESTIGATOR_3078] n of the Invest igator or 
designee.
3.History  of any illness that, i n the opi[INVESTIGATOR_3078] n of the Investigator or designee, might confound the 
resul ts of the study  or poses an addit ional risk to the subject by [CONTACT_337434].
4.History of cancer (m alignancy).
5.History  or presence of alcoho lism or drug abuse within the past [ADDRESS_915513] dosing. 
6.History  or presence of hypersensit ivity or idiosyncrati c reacti on to TAK -906 or rel ated 
compounds, or to esom eprazo le or PPIs (see NEXIUMÂ®USPI).
7.Female subjects of childbearing potential.
8.Female subjects with a positive pregnancy test or who is lactating.
9.Positive urine drug or alcoho l resul ts at screening or first check -in.
10.Positive urine cotinine at screening.
11.Positive results at screening for HIV, HBsAg, or HCV.
12.QTcF interval is >[ADDRESS_915514] igator or designee at screening.
13.Estimated creatinine clearance <90 mL/min at screening. 
14.Unable to refrain fro m or ant icipates the use of:
ï‚·Any drug, including prescription and non -prescri ption medicati ons (including PPIs, 
antacids, and H 2-antagonist), herbal remedies, or vitamin supplements within [ADDRESS_915515] dosing, acetaminophen (up to 2 g per 
24hours) may be administered at the discret ion of the Invest igator or desi gnee.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 29of 68
Protocol Final 04 Feb 2019
ï‚·Any drugs known to significant ly affect the absorption, distribution, metabo lism, or 
elimination of study  drugs (TAK -906 or esom eprazol e) wi thin [ADDRESS_915516] 
dosing and throughout the study . Appropri ate sources (eg, Flockhart TableTM) will  be 
consulted to confirm lack o f PK/pharmacodynamic interaction wit h study  drug.
15.Has been on a diet inco mpat ible with the on -study  diet, in the opi[INVESTIGATOR_3078] n of the Invest igator or 
designee, within the [ADDRESS_915517] dosing and throughout the study .
16.Donati on of blood or significant blood loss (eg, approximately 500 mL) within [ADDRESS_915518] ion or 
dosing, whichever is later, in the previous study  to Day 1 of Study  Period1 of the current 
study .
9.1.3 Medical History/Demography
Medical history  and dem ographic data, including name, sex, age, race, ethnicit y, and history  of 
tobacco use will b e recorded.
9.1.[ADDRESS_915519] ion [IP_ADDRESS] . All 
medicat ions taken by  [CONTACT_47378].
9.2 Clinical Procedures and Assessments
The Schedule o f Study  Procedures (Secti on3.0) summarizes the clinical procedures to be 
perform ed at each visit. Individual clinical procedures are described in detail below. Addit ional 
evaluations/testing may be deemed necessary  by [CONTACT_47384]/or the Sponsor 
for reasons rel ated to subject safet y.
For this study, the collect ion of blood for plasma TAK -[ADDRESS_915520] time po int as possible. All other procedures 
shoul d be com pleted as close to the prescribed/scheduled t ime as possible, but can be performed 
prior or after the prescribed/scheduled t ime.
Any nonscheduled procedures required fo r urgent evaluat ion of safet y concerns take precedence 
over all routine scheduled procedures.
9.2.1 Full Physical Exam
A full physical examinat ion will be performed as outlined in the Schedule o f Study  Procedures 
(Secti on3.0). Symptom -driven physical examinat ions may be performed at other times, if deemed 
necessary  by [CONTACT_47385].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 30of 68
Protocol Final 04 Feb 2019
9.2.2 Height and Weight
Body  height (cm) and weight (kg) will be reported as outlined in the Schedule of Study Procedures 
(Secti on3.0).
9.2.3 BMI
BMI will be calculated based on the height and weight measured at scree ning.
9.2.4 Vital Signs
Single measurements of body  temperature, respi [INVESTIGATOR_2842], bl ood pressure and heart rate, will be 
measured as outlined in the Schedule of Study  Procedures (Secti on3.0). Addit ional vital signs 
may be taken at any  other times, if deemed necessary .
Blood pressure and heart rate measurements will be performed with subjects in a supi[INVESTIGATOR_23571], 
except when they  are supi[INVESTIGATOR_1662] -recum bent because of study  procedures and/or AEs 
(eg,nausea, dizziness) or if deemed necessary by [CONTACT_47385]. Subjects should 
have rested in a supi[INVESTIGATOR_72126] 5 minutes before the measurements.
Blood pressure and heart rate will be measured within 24 hours prior to Day 1 dosing of each 
treatm ent peri od for the predose time point. When scheduled postdose, vital signs will be 
perform ed wi thin approximately 15 minutes of the scheduled time po int.
9.2.5 12-Lead ECG
Single 12 -lead ECGs will be perform ed as outlined in the Schedule of Study  Procedures 
(Secti on3.0). Addit ional ECGs may  be taken at any  other times, if deemed necessary  by[CONTACT_42038].
ECGs will be performed with subjects in a supi[INVESTIGATOR_676791] a 
supi[INVESTIGATOR_72126] [ADDRESS_915521] ion8.1.
Subjects will be instructed not to crush, split, or chew t he TAK -906 or esom eprazo le capsules. 
Capsules should be swallowed as who le.
Treatments A and B are described as: 
Study  Period 1 (Treatm ent A): 25 m g TAK -906 (1 x 25 mg TAK -906 capsule)
Study  Period 2 (Treatm ent B): 40 m g esomeprazole (1 x 40 mg NexiumÂ®capsule, or 
generic equivalent) QD for 5 days (Days 1 through 5 of 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -906
Study ID TAK -906-1006 Page 31of 68
Protocol Final 04 Feb 2019
Study  Period 2) wi th 25 m g TAK -906 (1 x 25 mg TAK -906 
capsule) administered [ADDRESS_915522] clock time of oral dosing will be recorded. 
9.2.7 AE Monitorin g
Subjects will be mo nitored throughout the study  for AEs to the study  formulations and/or 
procedures as described in Section 10.0.
9.2.8 Laboratory Procedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study  Procedures 
(Secti on3.0). In addit ion, laboratory  safet y tests may  be performed at various unscheduled time 
points, if deemed necessary  by [CONTACT_47385].
9.2.[ADDRESS_915523] of the following tests:
Hemoglobin Red blood cell count
Hematocrit Platelet count
Total and differential leukocyte count
Chemistry 
Serum  chemistry  tests will be performed after at least an [ADDRESS_915524]; however, in case o f dropouts 
or rechecks, subjects may  not have fasted for [ADDRESS_915525] chemistry  panel:
Total protein Albumin
Blood Urea Nitrogen Sodium
Bilirubin (total and direct) Potassium
Alkaline phosphatase Chloride
Aspartate aminotransferase (AST) Glucose 
Alanine aminotransferase (ALT) Creatinine *
* At screening, creatinine clearance will be calculated using the Cockcroft -Gault formula.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-[ADDRESS_915526] of the following tests:
pH Bilirubin
Specific gravity Blood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or le ukocyte esterase, a microscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.
Other 
HIV test Urine drug screen
Opi[INVESTIGATOR_858] (includes morphine, heroin (diacetylmorphine), 
codeine, 6-acetylmorphine, dihydrocodeine, hydrocodone, thebaine, and, hydromorphone)
AmphetaminesBarbiturates
Benzodiazepi[INVESTIGATOR_676792] (if antibody positive, confirm RNA negative)
Serum pregnancy test ( for females only )
FSH ( for postmenopausal females only )
Urine cotinine test
Urine alcohol screen
9.3 PK Samples
Primary specimen collection parameters are provided in  Table 9.a.  
For all subjects, blood samples for the determination of plasma TAK-906 will be collected at 
scheduled time points as delineated in the Schedule of Study Procedures (Section 3.0) in 4 mL 
blood collection tubes containing the appropriate ant icoagulant, respectively. The actual time of 
sample collection will be recorded on the source document in the case report form (CRF).  
 
Instruction for blood sampling, collection, pro cessing, and sample shipment will be provided 
separately.C
CI
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Userm
Te
licppxaminationminatio
morphinmorphi
acetylmocetylmo
done, thedone, th
taminesmines
ituratesurates
Benzodiazenzodi
CocainCoca
CaCct t
se
al
n parameparam
amples fmples
as delinas de
ubes contbes con
on will bn will
ctition fon forfff
paratelyaratelyFor a: Fo
TAK-906
Study ID TAK-906-1006 Page 33 of 68Protocol Final 04 Feb 2019
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample for PK Plasma PK analysis Mandatory
9.3.1 PK Measurements 
9.3.2 PK Measurements [IP_ADDRESS] Plasma PK Measurements
The PK parameters of TAK-906 will be derived using noncompartmental analysis methods and
will be determined from the concentration-time data for all evaluable subjects. Actual sampling
times, rather than scheduled sampling times, will be used in all PK computations involving
sampling times. A more detailed description will be given in the clinical pharmacology analysis 
plan.
PK parameters for plasma TAK-906 and  concentrations will be calculated as 
follows, as appropriate, following oral administration:
AUC last: The area under the concentration-time curve from time [ADDRESS_915527] quantifiable 
concentration.
AUC inf: Area under the concentration-time curve from time [ADDRESS_915528] quantifiable concentration.
Cmax: Maximum observed concentration.
Other PK parameters may be calculated if deemed necessary for the interpretation of the data. All 
efforts will be made to obtain the PK samples at  the exact nominal time relative to dosing. 
However, samples obtained within 10% of the no minal time from dosing will not be captured as a 
protocol deviation, as long as the exact time of the sample collection is noted on CRF.
The decision as to which plasma samples collected will be assayed for evaluation of PK will be 
determined by [CONTACT_456]. If indicated, these samples may also be assayed and/or pooled for assay 
in an exploratory manner for metabolites.CCI
CCI
CCI
Property of TakeOther PKOther PK
effortseffor
HowHocommximum obmum cial use onlytration:ation
ntrationration -tiand subject to the applic  Terms of Useionion
ndatoryatoryTe
rtmental menta
aluable sluable
n all PK call PK
n in the n in the
centrationentratio
of the lastf the laly an
mmercia
keda: For non-coCCI
TAK-906
Study ID TAK-906-1006 Page 34 of 68Protocol Final 04 Feb 2019
9.3.3  
9.3.4 Confinement
In Study Period 1, subjects will be housed on Day -1, at the time indicated by [CONTACT_676805] 48-hour blood draw and/or study procedures on Day 3. In Study Period 2, Subjects will be 
housed on Day 3 at the time indicated by [CONTACT_676806] 48-hour blood draw and/or study 
procedures on Day 6.
Subjects will return for dosing and/or study procedures as indicated in the Schedule of Study 
Procedures (Section 3.0). A subject may be required to remain at the CRU for longer at the 
discretion of the Investigator or designee.
As per site preference, subjects may be confined throughout the washout period.CCI
CCI
Property of [COMPANY_005]: For non-commercial use only and subj1, at the at th
on Dayon Day 3y
CRU untRU unt i
tudytudy propryy
maymay bby[CONTACT_233300] r
desisigneegne
cts mays may by[CONTACT_676807] -[ADDRESS_915529] who has 
signed inform ed consent to participate in a study; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
ï‚·Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
ï‚·Necessitate therapeutic intervent ion.
ï‚·Requi re an invasive diagnostic procedure.
ï‚·Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
ï‚·Be considered unfavorable by [CONTACT_4168].
Diagnoses versus signs and symptoms:
ï‚·Each event should be recorded to represent a single diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs.If a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
ï‚·Changes in laboratory  values or ECG param eters maybe considered AEs if they are judged to 
be clinically  significant (i e, if some act ion or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
ï‚·If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
ï‚·A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condition and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  procedure. However, if the subject experiences a worsening or complicat ion 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 36of 68
Protocol Final 04 Feb 2019
of such a concurre nt medical  history  condi tion, the worsening or complication should be 
recorded appropriately as an AE (worsening or complicat ion occurs after informed consent is 
signed). Invest igators should ensure that the event term recorded captures the change in the 
condition (eg, â€œworsening ofâ€¦â€).
ï‚·If a subject has a pre -exist ing epi[INVESTIGATOR_45283] (eg, asthma, epi[INVESTIGATOR_002]), any occurrence of an 
epi[INVESTIGATOR_55723], serious, or 
severe in nature, that is, invest igators shoul d ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg â€œworsening ofâ€¦â€).
ï‚·If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captu red as an AE if occurring to a greater extent to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, â€œworsening ofâ€¦â€).
Worsening of AEs:
ï‚·If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
shoul d be recorded as a new AE. Invest igators should ensure that the AE term recorded 
captures the change in the condi tion (eg, â€œworsening ofâ€¦â€).
Changes in severit y of AEs:
ï‚·If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
ï‚·Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worseni ng of the pre -exist ing condit ion, the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
ï‚·Elect ive procedures performed where th ere is no change in the subjectâ€™s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subjectâ€™s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
ï‚·An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the investigator or the reporting physician to d ecide 
whether a dose is to be considered an overdose, in consultation wit h the Sponsor.
ï‚·All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the (e)CRF, in order to capture this important safet y information consi stent ly in the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 37of 68
Protocol Final 04 Feb 2019
database. AEs associated with an overdose will be documented on AE CRF(s) according to 
Secti on 10.0.
ï‚·Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion 10.2.8 .
ï‚·In the event of drug overdose, the subject should be treated sym ptom atically.
10.1.[ADDRESS_915530] medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
ï‚·The term â€œlife threateningâ€ refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT assessed by [CONTACT_81707]/or the Sponsor, that 
satisfies any  of the f ollowing:
ï‚·May require intervent ion to prevent items 1 through 5 above.
ï‚·May expose the subject to danger, even though the event is not immediat ely life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
ï‚·Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915531] 
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_4072] / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal product Toxic epi[INVESTIGATOR_194]/
Stevens -Johnson syndromeNeuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections 10.1 and 10.1.1 ).
10.1.[ADDRESS_915532] AEs
NA
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The PI [INVESTIGATOR_676793] (refer to 
Secti on 10.2.2 ). All AEs, including signs, symptoms, or clinically significant treatment -emergent 
laboratory  abnorm alities will be graded on the National Cancer Institu te (NCI) Commo n 
Termino logy Cri teria for Adverse Events (CTCAE) Version 5.0 toxicit y grading scale. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 39of 68
Protocol Final 04 Feb 2019
Grade refers to the severit y of the AE. The CTCAE di splays Grades 1 through 5 with unique 
clinical descript ions of severit y for each AE based on the fo llowing general guideline [ 9]:
Grade 1 Mild; asymptomat ic or mild symptoms; clinical or diagnostic observat ions only; 
intervent ion not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervent ion indicated; limit ing 
age-appropriate instrumental ADL*.
Grade 3 Severe or m edically  significant but not immediately  life threatening; 
hospi [INVESTIGATOR_76667]; disabling; limit ing 
self-care ADL**.
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death rel ated to AE.
A Semi -colon indicates â€˜orâ€™ within the description of the grade.
Note: Not all grades are appropriate for all AEs. T herefore, some AEs are listed within the CTCAE with fewer than 
5options for grade selection. Grade 5 (death) is not appropriate for some AEs and therefore is not an option. 
ADL= Activities of Daily Living 
* Instrumental ADL refer to preparing meals, shop pi[INVESTIGATOR_3112], using the telephone, managing money, 
etc.
** Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including the course after withdrawal o f the drug), or for whi ch a causal  
relationship is a t least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out , although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  [CONTACT_1604], such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.[ADDRESS_915533] signs/symptoms were noted by [CONTACT_3184]/or 
investigator.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915534] died.
10.2.5 Pattern of Adverse E vent (Frequency) 
Epi[INVESTIGATOR_39751] c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
ï‚·Drug withdrawn â€“a study  medicat ion is stopped due to the particular AE.
ï‚·Dose not changed â€“the particular AE did not require stoppi[INVESTIGATOR_007] a study  medicat ion.
ï‚·Unknown â€“only to be used if it has not been possible to determine what action has been taken.
ï‚·Not applicable â€“a study  medicat ion was stopped for a reason othe r than the particular AE 
eg,the study  has been terminated, the subject died, dosing with study  medicat ion had not y et 
started or dosing wit h study  medicat ion was already  stopped before the onset of the AE.
ï‚·Dose reduced â€“the dose was reduced due to the pa rticular AE.
ï‚·Dose increased â€“the dose was increased due to the particular AE.
ï‚·Drug interrupted â€“the dose was interrupted due to the particular AE.
10.2.7 Outcome 
ï‚·Recovered/reso lved â€“ subject returned to first assessment status with respect to the AE.
ï‚·Recoverin g/resolving â€“ the intensit y is lowered by  [CONTACT_45332] m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died fro m a cause other 
than the particular AE with the condit ion rem aining â€œrecovering/resolving.â€
ï‚·Not recovered/not resolved â€“there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  ofthe observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining â€œNot recovered/not 
resolved.â€
ï‚·Recovered/ Reso lved wit h sequelae â€“the subjec t recovered from an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
ï‚·Fatal  â€“an AE that is considered as the cause of death.
ï‚·Unknown â€“the course of the AE cannot b e followed up due to hospi [INVESTIGATOR_47350]â€™s participation in the study .
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915535] AEs, and Abnormal LFTs
[IP_ADDRESS] Collection Period
Collect ion of AEs (ie, AEs, SAEs, Special Inte rest AEs, and Abnormal LFTs) will co mmence at 
the time the subject signs the informed consent. Routine co llection of AEs will cont inue until the 
follow-up visit on Day [ADDRESS_915536] discont inues study 
participat ion. 
[IP_ADDRESS] Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as â€œHow have you been f eeling since y our l ast visit ?â€ may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing an 
SAE prior to the first exposure to invest igational product must be monitored un til the symptom s 
subside and any clin ically relevant changes in laboratory values have returned to Baseline or there 
is a sat isfactory  explanat ion for the change. Nonserious AEs that begin prior to the first exposure 
to invest igational product, related or unrelated to the study procedure, nee d not be fo llowed-up for 
the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All AEs will be documented in the AE page of the CRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
ï‚·Event term .
ï‚·Start and end date and time.
ï‚·Pattern of AE (frequency).
ï‚·Severit y/Intensi ty.
ï‚·Causalit y (Invest igatorâ€™s opi[INVESTIGATOR_3078] n of the causal relationship between the event and 
administration of study  drug[s] ).
ï‚·Action taken with study  drug.
ï‚·Outcom e of event.
ï‚·Seriousness.
[IP_ADDRESS] Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915537] onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
ï‚·A short descript ion of the event and the reason why  the event i s categori zed as serious.
ï‚·Subject identificat ion number.
ï‚·Invest igatorâ€™s name.
ï‚·Nam e of the study  medicat ion(s).
ï‚·Causalit y assessment.
The SAE form should be transmitted within [ADDRESS_915538] report becomes available at a later date, the 
investi gator shoul d com plete a follow -up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copi[INVESTIGATOR_1672] 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem result s) shoul d be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
[IP_ADDRESS] Reporting Special Interest AEs 
NA
[IP_ADDRESS] Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3 Ã—ULN on [ADDRESS_915539] >3 Ã—ULN and total bilirubin >2 Ã—ULN for which an 
alternat ive etio logy has not been i dentified, the event shoul d be recorded as an SAE and reported 
as per Secti on [IP_ADDRESS] . The i nvest igator must contact [CONTACT_55741] n of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute live r disease. Follow -up laboratory  tests as described in Section 9.2.[ADDRESS_915540] also be 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915541] be completed and transmi tted with the [COMPANY_005] 
SAE form (as per Section 10.2.9 ). 
10.2.[ADDRESS_915542] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory  authori ties, invest igators and IRBs or 
IECs, as applicable, in accordance with nat ional regulat ions in the countr ies where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the Sponsor or 
Sponsorâ€™s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_915543] a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h national regulat ions.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK-[ADDRESS_915544] ical analyses of the d ata collected in this study will 
be documented in a SAP. The SAP will be prepared by [CONTACT_676808]. This document may modify the plans outlined in the protocol; however, any major 
modifications of the primary endpoints definition  and/or its analysis will also be reflected in a 
protocol amendment. Additional statisti cal analyses other than those described in this section may 
be performed if deemed appropriate.
11.1.1 Analysis Sets
[IP_ADDRESS] Safety Set
All subjects who received at least one dose of the study drug will be included in the safety 
evaluations.
[IP_ADDRESS] PK Set
Samples from all subjects will be assayed even if the subjects do not complete the study. All 
subjects who comply sufficiently with the protocol and display an evaluable PK profile (eg, 
exposure to treatmen t, availability of measurements and absence of major protocol violations) will 
be included in the statistical analyses.
[IP_ADDRESS] PD Set
NA
11.1.2 Analysis  of Demography and Other Baseline Characteristics
Continuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statistics. Categorical demographic data (ie, gender, race, and 
ethnicity) will also be listed and tabulated.
11.1.3 PK Analysis
Descriptive statistics will be provided for the plasma TAK-906 concentrations using appropriate 
summary statistics to be fully specified in the SAP.
PK parameters for plasma TAK-906 concentrations will be calculated as described in 
Section [IP_ADDRESS].
For evaluation of potential effect of esomeprazole on TAK-[ADDRESS_915545], and AUC inf. The ANOVA model will include treatment as CCI
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Useyywillwillyy
he 
major 
flected inflect
this secthis se
will be inill be i
the subjee subj
ocol and col an
ements aments
graphyraphy
hic data c data
ummary mma
so be lisbe l
AnalysiAnaly
ptive stative st
mary stamary st
PK paramPK par
SectiSect
yoCCC
TAK -[ADDRESS_915546] -squares 
means (LSM) as well as the difference between treatment LSM. The geometric mean of the 
relative bioavailabilit y of the TAK -906 wi th esomeprazole regimen relative to the TAK -906 
regimen alo ne and the associated 90% CIs will be determined by [CONTACT_676809] -transform ed param eters
11.1.[ADDRESS_915547].
Quant itative safet y data as well as the difference to baseline, when appropriate, will be 
summarized using the appropriate descriptive statistics.[IP_ADDRESS] AEs
AEs will be coded using the most current version of Med ical Dict ionary for Regulatory  Activit ies 
(MedDRA
Â®) available at Celerio n and summarized by [CONTACT_676810]. A by -subject AE data list ing 
including verbat im term, coded term, treatm ent, severi ty, and rel ationship to treatment will be 
provi ded.
[IP_ADDRESS] Clinical Laboratory Evaluation
Clinical laboratory  resul ts will be summarized by [CONTACT_47395] a 
shift table describing out of normal range shifts w ill be provided.
[IP_ADDRESS] Vital Signs and ECG Parameters
Vital signs and ECG assessments will be summarized by [CONTACT_676811].
[IP_ADDRESS] Physical Examination 
Physical examinat ion findings will be presented in the data list ings.
11.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
11.3 Determination of Sample Size
The total of twelve (12) subjects will be enrolled in this study . Thi s sam ple size will provi de at 
least 80% power to conclude the C maxof TAK -906 will not decr ease more than 50% in the 
presence of eso meprazo le, assuming that the intra- subject %CV for C maxof TAK -906 will not 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 46of 68
Protocol Final 04 Feb 2019
exceed 45% and a true ratio of 0.8. Lower intra- subject variabilit y was observed for AUC in 
previous studies; therefore, the power is expected to be greater for AUC.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915548] igator and study site guarantee access to source documents by [CONTACT_152486] (Contract Research Organizatio n) and by [CONTACT_4186].
All aspects of the study  and i ts docum entati on will be subject to review by [CONTACT_47399]â€™s designee (as lo ng as blinding is not jeopardized), including but not limited to the 
Invest igatorâ€™s Binder, study  drug, subject medical records, informed consent documentation, and 
review of CRFs and associated source documents. It is important that the invest igator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to t he 
process.
12.[ADDRESS_915549] to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specifie d procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. 
12.[ADDRESS_915550] the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies wher e laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by [CONTACT_17513], including 
those of foreign governm ents (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contact[CONTACT_4190] a regulatory  body , the Sponsor should be notified 
immed iately. The investigator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion 12.1.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915551] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the International Council for Harmins ation (ICH) Harm onised Tri partite Gui deline 
for GCP. Each invest igator will conduct the study according to applicable local or regional 
regul atory  requi rements and align his or her conduct in accordance with the â€œResponsibilit ies of 
the Invest igatorâ€ that are listed in Appendix A. The principles of Helsinki are addressed through 
the protocol and through appendices containing requirements for informed co nsent and 
investigator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing region. The Sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwillin g to provi de names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by [CONTACT_9930].
The Sponsor or designee will supply  relevant documents for submission to the respective IRB or 
IEC for the protocolâ€™s review and approval. This protocol, the Invest igatorâ€™s Brochure, a copy o f 
the ICF, and, if applicable, subject recruitment materials and/or advertisements and other 
docum ents requi red by [CONTACT_126950] l aws and regul ations, m ust be submitted to a central or local 
IRB or IEC for approval. The IRBâ€™s or IECâ€™s written approval o f the protocol  and subject 
inform ed consent m ust be obtained and submitted to the Sponsor or des ignee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activit y). The IRB or IEC approval must refer to the study  by [CONTACT_45343], 
number, and versio n date; ident ify versio ns of other do cuments (eg, ICF) reviewed; and state the 
approval  date. The Sponsor will ship drug/notify sit e once the Sponsor has confirmed the adequacy 
of site regulatory  docum entati on and, when applicable, the Sponsor has received permissio n from 
competent authori ty to begin the study . Until the site receives drug/notificat ion no protocol 
activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by  [CONTACT_4195]. This may include 
notification to the IRB or IEC regarding protocol  amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  [CONTACT_1766], l ocal safety reporting requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by [CONTACT_4196], and submissio n of the invest igatorâ€™s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the Sponsor or its 
designee.Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by [CONTACT_47400].
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915552] authorizat ion form (if applicable), and subject 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosure s of the subjectâ€™s personal and personal healt h informat ion for purposes of conducting 
the study . The ICF and the subject informat ion sheet (if applicable) further explain the nature of 
the study , its obj ectives, and potential risks and benefits, as well a s the date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the subject authorizat ion form. The ICF, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by [CONTACT_676812].The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective subject. It is the 
responsibilit y of the inve stigator to explain the detailed elements of the ICF, subject authorizat ion 
form (if applicable), and subject informat ion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possible and in the manner de emed 
appropriate by [CONTACT_4186]. In the event the subject is not capable of rendering adequate written 
inform ed consent, then the subjectâ€™s legally  acceptable representative may  provide such consent 
for the subject in accordance with applicable laws and regulati ons.
The subject, or the subjectâ€™s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subjectâ€™s legally  acceptable representative, determines he or she will part icipate in 
the study , then the ICF and subject authorizat ion form (if applicable) must be signed and dated by 
[CONTACT_423], or the subjectâ€™s legally acceptable representative, at the time of consent an d prior to the 
subject entering into the study . The subject or the subjectâ€™s legally  acceptable representative 
shoul d be instructed to si gn using thei r legal names, not ni cknames, using blue or black ballpo int 
ink. The investigator must also sign and date the ICF and subject auth orization (if applicable) at 
the time of consent and prior to subject entering int o the study; however, the Sponsor may allow a 
designee of the investigator to sign to the extent permitted by  [CONTACT_54003] l aw.
Once signed, the origina l ICF, subject authori zation form (if applicable), and subject informat ion 
sheet (if applicable) will be stored in the investigatorâ€™s site file. The investigator must document 
the date the subject signs the informed consent in the subjectâ€™s medical record. Copi [INVESTIGATOR_304508], the signed subject authorizat ion form (if applicable), and subject informat ion sheet (if 
applicable) shall be given to the subject.
All revised ICFs must be reviewed and signed by [CONTACT_174388]â€™s legal ly 
acceptable representative in the same manner as the original informed consent. The date the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915553]â€™s medical record, and the subject 
shoul d receive a copy  of the revised ICF.
Subjects who consented and provided a blood sample for DNA analysis can withdraw their 
consent and request disposal o f a stored sample at any time prior to analysis. Notify Sponsor of 
consent withdrawal.
13.[ADDRESS_915554]â€™s right to protection 
against invasio n of privacy. Throughout this study , a subjectâ€™s source data will only be linked to 
the Sponsorâ€™s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by [CONTACT_21129] a pplicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subjectâ€™s unique 
ident ificat ion number.
To comply wit h ICH Guidelines for GCP and to verify co mpliance with this protocol, the Sponsor 
requi res the investigator to permit its monitor or designeeâ€™s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medica l Devices Agency), the Sponsorâ€™s designated auditors, and the 
appropriate IRBs and IECs to review the subjectâ€™s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and d ischarge summaries for hospi[INVESTIGATOR_45291] a subjectâ€™s study participation, 
and autopsy  reports. Access to a subjectâ€™s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Secti on 13.2).
Copi [INVESTIGATOR_47351] (ie, subject name, address, and other ident ifier fields 
not collected on the subjectâ€™s CRF).
13.[ADDRESS_915555] igators or to regulatory  agencies, except as required by  
[CONTACT_4201]. Except as ot herwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the Sponsor.
The Sponsor may publish any data and information fro m the study (including data and informat ion 
generated by  [CONTACT_3170]) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately ref lect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinica l Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 51of 68
Protocol Final 04 Feb 2019
13.4.2 Clinical Trial Registration 
In order to ensure that information on clinical studies reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, [COMPANY_005] will, at a minimum register all 
intervent ional clinical studys it Sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in [COMPANY_005] Policy/Standard . [COMPANY_005] 
contact [CONTACT_4203], along with invest igatorâ€™s cit y, state (for American investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist callers in lo cating study  sites cl osest to thei r homes by 
[CONTACT_45344], address, and phone number to the callers request ing study  
inform ation. Once subjects receive invest igator contact [CONTACT_4203], they  may call  the si te 
requesting enrollment into the study . The invest igative sites are encouraged to handle the study  
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of study  enro llment, th ey shoul d be referred to the Sponsor.
Any investigator who objects to the Sponsor provi ding this informat ion to callers must provide the 
Sponsor with a written notice requesting that their informat ion not be listed on the registry  site.
13.4.[ADDRESS_915556] the results of clinical studies on ClinicalTrials.gov or other publicly  accessible 
websites, as required by [CONTACT_39825]/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Refer to the study  site agreement regardi ng the Sponsorâ€™s policy  on subject com pensati on and 
treatm ent for injury. If the invest igator has questions regarding this policy, he or she should contact 
[CONTACT_13679]â€™s designee.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK-[ADDRESS_915557] Type / Role
Serious adverse event and pregnancy reporting[COMPANY_003]
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Usee applic
TAK -[ADDRESS_915558] igatorâ€™s Brochure, package 
insert and any other product informat ion provi ded by  [CONTACT_1034]. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
ï‚·The ethical principles that have their origin in the Declaration of Helsinki.
ï‚·International Council for Harmonisat ion, E6 Good Clinical Practice: Conso lidated Guideline.
ï‚·All applicable laws and regulat ions, includi ng, wi thout limi tation, data privacy laws and 
regul ations.
ï‚·Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2.9 of this 
protocol .
ï‚·Terms outlined in the study  site agreement.
ï‚·Responsibilit ies o f the Invest igator ( Appendix A).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature [CONTACT_4235] (print or ty pe)
Invest igatorâ€™s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915559] ivities in full or in partnership wi th the Sponsor.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915560] Aspartate aminotransferase
AUC Area under the concentration -time curve
AUC %extrap Percent of AUC âˆžextrapolated 
AUC last Area under the concentration -time curve, from time [ADDRESS_915561] variability
ECG Electrocardiogram
FDA Food and Drug Administration
FSH Follicle -stimulating hormone
g Gram(s)
GCP Good Clinical Practice
HBsAg Hepatitis B surface antigen
hCG Human chorionic gonadotropin
HCV Hepatitis C virus 
HIV Human immunodeficiency virus
IB Investigatorâ€™s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IRB Institutio nal Review Board
Kel Apparent first -order terminal elimination rate constant
kg Kilogram
LFT Liver function test(s)
ln Natural log
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915562] -squares
m2Meters squared
MedDRAÂ®Medical Dictionary for Regulatory ActivitiesÂ®
mg Milligram
mL Milliliter
mmHg Millimeter of mercury
msec Millisecond
n Sample size
NA Not applicable
NMDA N-methy l-D-aspartate
oz Ounce
OATP Organic anion -transporting polypeptide
PK Pharmacokinetic(s)
PO Oral administration
PPI [INVESTIGATOR_676794]â€™s formula
SAE Serious adverse event
SAP Statistical analysis plan
S[LOCATION_003]R Suspected unexpected serious adverse reactions
tÂ½ Apparent first -order terminal elimination half -life
TEAE Treatment -emergent adverse event
Tmax Time to reach maximum observed concentration [C max]
ULN Upper limit of normal
US [LOCATION_002]
[LOCATION_003] [LOCATION_002] of America
WHO World Health Organization
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 57of 68
Protocol Final 04 Feb 2019
15.0 DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_85958].
15.1 CRFs (Electronic and/or Paper)
The Sponsor or its designee will supply invest igative sites with access to CRFs. The Sponsor or its 
designee will train appropriate site staff in the use of the CRF. These forms are used to transmit the 
inform ation collected in the performance of this study  to the Sponsor and regulatory  authori ties. 
CRFs must be completed in English. 
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and quest ionable values. Queries may  be issued by [CONTACT_1748] (or designees) and will be answered by [CONTACT_779]. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correctio n, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the CRFs for completeness and accuracy and must sign and 
date the appropriate CRFs as indicated. Furthermore, the invest igator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the CRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the CRF s should be made by [CONTACT_437631]. The principal invest igator must review the data change for completeness and accuracy, and 
must si gn and date . 
CRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by [CONTACT_39810]. The Sponsor or i ts desi gnee will  be permi tted to revi ew the subjectâ€™s medical 
and hospi[INVESTIGATOR_47354]. The com pleted CRFs 
are the sole property  of the Sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the Sponsor.
15.[ADDRESS_915563] igator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from  the inform ed consent forms), 
copy  of CRFs, including the audit trail, and detailed records of drug disposit ion to enable 
evaluat ions or audits from regulatory  authori ties, the Sponsor or i ts desi gnees. Any source 
docum entati on printed on degradable thermal sensitive paper should be photocopi[INVESTIGATOR_47355] h the original in the subjectâ€™s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 Secti on 4.9.5 requi res the investigator to retain essent ial docum ents spec ified in ICH E6 
(Secti on 8) until at least [ADDRESS_915564] approval of a market ing applicat ion for a specified 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915565] igator and Sponsor. 
Refer to the Clinical Study  Site Agreement for the Sponsorâ€™s requirements on record retention. 
The invest igator and the head o f the inst itution shoul d contact [CONTACT_676813].
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 59of 68
Protocol Final 04 Feb 2019
16.0 REFERENCES
1.Parkm an HP, Hasl er WL, Fisher RS, American Gastroenterological A. American 
Gastroenterological Associat ion technical review on the diagnosis and treatment of 
gastroparesi s. Gastroenterology  2004;127(5):1592-622.
2.Camil leri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American Co llege o f G. Clinical 
guideline: m anagement of gastroparesis. Am J Gastroenterol 2013;108(1):18- 37; quiz 8.
3.Hyett B, Martinez FJ, Gill BM, Mehra S, Lembo A, Kelly CP, et al. Delayed radionucleotid e 
gastri c empt ying studies predict morbidit y in diabeti cs wi th symptom s of gastroparesis. 
Gastroenterology  2009;137(2):445-52.
4.[COMPANY_005] Pharmaceuticals, Inc. Global Invest igator Brochure. Edition 2.0, July 2018.
5.NEXIUMÂ®delayed -release 20 and 40 m g capsules , [COMPANY_008] Pharms, label, 07 June 2018 
Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021153s053,022101s017,[ZIP_CODE]
7s020lbl.pdf
6.NEXIUMÂ®FDA review of NDA 21 -153/21- 154 for [COMPANY_008] Pharmaceut icals 
Esom eprazo le Magnesium Delayed- Release Capsules, March 12, 1999. Available at: 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
7.Andersson T 1,RÃ¶hss K,Bredberg E ,Hassan -Alin M . Pharm acokinet ics and 
pharmacodynamics of eso meprazo le, the S -isomer of omeprazo le. Aliment Pharmacol 
Ther. [ADDRESS_915566];15(10):[ADDRESS_915567] O ,Nyman L . Esom eprazo le 40 mg 
provi des improv ed intragastric acid control as compared with lansoprazole 30 mg and 
rabeprazo le 20 mg in healt hy volunteers. Digesti on.2003;68(4):[ADDRESS_915568] itute (NCI) Commo n Termino logy Criteria for Adverse Events (CTCAE) 
Versi on 5.0 toxi city grading scale . 27Nov2017.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 60of 68
Protocol Final 04 Feb 2019
17.0 APPENDICES
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915569] igators by  [CONTACT_45348] â€œStatement of Invest igatorâ€ (Form FDA 1572), which must be completed and 
signed before the invest igator may participate i n this study .
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/in stitution retains the services of any  individual  or party  to perform  
study  -related duti es and funct ions, the investigator/inst itution shoul d ensure that this 
individual or party is qualified to perform those study -related duti es and funct ions and should 
implement procedures to ensure the integrity  of the study -related duti es and funct ions 
perform ed and any  data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed o n potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by [CONTACT_4215]/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IE C all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within [ADDRESS_915570]â€™s medical chart. Valid informed consent is the most current 
version approved by [CONTACT_1201]/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subjectâ€™s personal 
inform ation (including personal health informat ion) that will take place in connect ionwith the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subjectâ€™s legally acceptable representative.
9.Prepare and maintain a dequate case histori es of all persons entered into the study , incl uding 
CRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a minimum of 
2years fo llowing notificat ion by [CONTACT_676814] o r 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915571] and receive written approval fro m the Sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by [CONTACT_4216] -specified essent ial 
docum ents.
11.Maintain current records of the receipt, administratio n, and disposit ion of Sponsor -supplied 
drugs, and return all unused Sponsor -supplied drugs to the Sponsor. 
12.Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915572], as 
applicable:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subjectâ€™s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subjectâ€™s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or cours es of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibi lity that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  [CONTACT_2960] a written informed consent form, the 
subject or the subjectâ€™s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact [CONTACT_39831] 
(invest igator), subj ectâ€™s ri ghts, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915573]â€™s 
legally acceptable representative may discont inue participat ion at any  time wi thout penal ty or 
loss of benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subjectâ€™s decisio n to wi thdraw from the research and procedures for 
orderly terminat ion of part icipation by [CONTACT_423].
21.A statement that the subject or the subjectâ€™s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relev ant to the subjectâ€™s 
willingness to continue participat ion in the study .
22.A statement that results of DNA analysis will not be disclo sed to an individual, unless 
prevailing laws require the Sponsor to do so.
23. The foreseeable circumstances or reasons under wh ich the subjectâ€™s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and disclosures of the subjectâ€™s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subjectâ€™s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  [CONTACT_45351] y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assist ing [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal he alth informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, [COMPANY_005] will make every  effort to keep y our pers onal information confident ial, 
and y our name [CONTACT_39846] [CONTACT_2371];
c)that personal information (including personal healt h informat ion) may be added to 
[COMPANY_005]â€™s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subjectâ€™s ident ity will remain confident ial in the event that study  resul ts are 
published.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915574] ive contraceptio n (as defined in the informed consent) 
from signing of informed consent throughout the duration of the study  and through to the 
follow-up visit (i e, [ADDRESS_915575] dose of TAK -906). 
26.A statement that clinical study informat ion from this study will be publicly disclo sed in a 
publicly  accessible website, such as ClinicalTrials.gov.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915576] igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, inv estigatorâ€™s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
ï‚·[COMPANY_005], its affiliates, and licensing partners.
ï‚·Business partners as sisting [COMPANY_005], its affiliates, and licensing partners.
ï‚·Regulatory  agencies and other health authorit ies.
ï‚·IRBs and IECs.
Invest igatorâ€™s personal informat ion may be retained, processed, and transferred by  [CONTACT_39833]:
ï‚·Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
ï‚·Management, monitoring, inspect ion, and audit of the study .
ï‚·Analysis, review, and verificat ion of the study  results.
ï‚·Safety reporti ng and p harmacovigilance relat ing to the study .
ï‚·Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
ï‚·Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the same chemical com pound present in the study  medicat ion.
ï‚·Inspect ions and invest igations by [CONTACT_4218].
ï‚·Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and licensing partners.
ï‚·Archiving and audit of study  records.
ï‚·Posting investigator site contact [CONTACT_4203], study details and results on publicly accessible 
clinical study registri es, databases, and websi tes.
Invest igatorâ€™s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igatorâ€™s own 
country .
Invest igator acknowledges and consents to th e use of his or her personal information by [CONTACT_47407].
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -906
Study ID TAK -906-1006 Page 67of 68
Protocol Final 04 Feb 2019
Appendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Subjects and Their Female Part ners
From  signing of informed consent, throughout the duration of the study , and through to the 
follow-up visit, nonsterilized** male subjects who are sexually act ive with a female partner of 
childbearing potential* must use barrier contraceptio n (eg, condom  with spermicidal cream or 
jelly). In addition, they  must be advised not to donate sperm during this period. Females o f 
childbearing potential who are partners of male subjects are also advised to use addit ional 
contraception as shown in the list contain ing highly  effect ive/effect ive contraception below.
Female Subjects and Their Male Partners
*A wo man is considered a woman of childbearing potential (WOCBP), ie, fert ile, following 
menarche and unt il beco ming post -menopausal unless permanent ly sterile. Per manent sterilizat ion 
methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilizat ion, and bilateral 
tubal  ligation or bilateral salpi[INVESTIGATOR_1656] . A postm enopausal  state is defined as no menses for [ADDRESS_915577] imulat ing hormone (FSH) level in 
the postm enopausal  range (FSH >40 IU/L) may  be used to confirm a post -menopausal state in 
younger wom en (eg, those <45 y ear ol d) or wom en who are not using hormonal contraception or 
horm onal replacemen t therapy . However, in the absence of 12 months o f amenorrhea, a single 
FSH m easurement is insufficient. 
** Sterilized males should be at least [ADDRESS_915578] had bilateral 
orchi dectomy .
1.Unacceptable methods of contraception are:
ï‚·Spermicides only .
ï‚·Withdrawal.
ï‚·No m ethod at all.
ï‚·Use of female and male condoms together.
ï‚·Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
ï‚·Sexua l abst inence is NOT an acceptable method of contraception.
2.Subjects will be provided with information on highly effect ive/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating th at they  understand the requirements for avoidance of pregnancy, 
donati on of  ova, and sperm donat ion during the course of the study .
3.During the course of the study, regular serum human chorionic gonadotropin (hCG) pregnanc y 
tests will be performed for all w omen only  and all subjects (male and female) will receive 
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
TAK -[ADDRESS_915579] to the avo idance of pregnancy and sperm donat ion as part of 
the study  procedures. Such guidance should include a reminder of the following:
a)contraceptive requirements of the study .
b)reasons for use of barrier methods (ie, condom) in males with pregnant partners.
c)assessment of subject compliance through questions such as
i.Have you used the contraception consistent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Is there a chance for a female partner who could become pregnant?
Pregnancy
Women of childbearing potential will not be included in this study .
Any pregnancies in the partner of a male subject during the study  and until the fo llow up visi t, 
shoul d be recorded following authorizat ion from the subjectâ€™s partner. 
If female partner of a male subject agrees to the primary  care physician being informed, the 
investigator should notify the primary care physician that the subject was participat ing in a clinica l 
study  at the time his female partner became pregnant and provide details of the study  drug the 
subject received (blinded or unblinded, as applicable).
All pregnancies in female partners o f male subjects will be fo llowed up to final outcome, using the 
pregnancy form. The outcome, including any premature terminat ion, must be reported to the 
sponsor. An evaluation after the birth of the child will also be conducted.
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use
ä¢¢
ä¢¢ä¢¢ä¢¢
ä¢¢
ä¢¢ä¢¢
ä¢¢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm â€˜UTCâ€™) 

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GDGä£ƒä¢¢ä£•ä£«ä£°ä£©ä£®ä£§ä¢¯ä£•ä£§ä£³ä£·ä£§ä£°ä£¥ä£§ä¢®ä¢¢ä£‘ä£²ä£§ä£°ä¢¯ä£Žä££ä£¤ä£§ä£®ä¢®ä¢¢ä¢´ä¢¯ä£’ä£§ä£´ä£«ä£±ä£¦ä¢®ä¢¢ä£…ä£´ä£±ä£µä£µä£±ä£¸ä£§ä£´ä¢¢ä£•ä£¶ä£·ä£¦ä£»ä¢¢ä£¶ä£±ä¢¢ä£‡ä£¸ä££ ä£®ä£·ä££ä£¶ä£§ä¢¢ä£¶ä£ªä£§ä¢¢ä£‡ä£¨ä£¨ä£§ä£¥ä£¶ä¢¢ä£±ä£¨ä¢¢ä£¶ä£ªä£§ä¢¢ä£’ä£´ä£±ä£¶ä£±ä£°ä¢¢ä£’ä£·ä£¯ä£²ä¢¢ä£‹ä£°ä£ªä£«ä£¤ä£«ä£¶ä£±ä£´
ä£‡ä£µä£±ä£¯ä£§ä£²ä£´ä££ä£¼ä£±ä£®ä£§ä¢¢ä£±ä£°ä¢¢ä£¶ä£ªä£§ä¢¢ä£•ä£«ä£°ä£©ä£®ä£§ä¢¯ä£†ä£±ä£µä£§ä¢¢ä£’ä£ªä££ä£´ä£¯ä££ä£¥ä£±ä£­ä£«ä£°ä£§ä£¶ä£«ä£¥ä£µä¢¢ä£±ä£¨ä¢¢ä£‘ä£´ä££ä£®ä¢¢ä£–ä£ƒä£ä¢¯ä¢»ä¢² ä¢¸ä¢¢ä£«ä£°ä¢¢ä£Šä£§ä££ä£®ä£¶ä£ªä£»ä¢¢ä£ƒä£¦ä£·ä£®ä£¶ä¢¢ä£•ä£·ä£¤ä£¬ä£§ä£¥ä£¶ä£µ
&OLQLFDO3KDUPDFRORJ\$SSURYDO )HE87&
&OLQLFDO6FLHQFH$SSURYDO )HE87&
%LRVWDWLVWLFV$SSURYDO )HE87&[COMPANY_003]
Property of [COMPANY_005]: For non-commercial use only and subject to the applic  Terms of Use Tate 
HH:mm â€˜UT
87&8

)HE)HE